Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 6/20 | 0.52 |
| ▸ | HTR7 | P34969 | 2/20 | 0.49 |
| ▸ | PPARG | P37231 | 1/20 | 0.49 |
| ▸ | PPARA | Q07869 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.47 |
| ▸ | LMNA | P02545 | 4/20 | 0.47 |
| ▸ | MAPT | P10636 | 5/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.44 |
| ▸ | HTR1A | P08908 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4588328 | 0.99 | SIGMAR1 (0.51) | SIGMAR1HTR7PPARGPPARAKDM4E | |
| SCHEMBL4589148 | 0.97 | SIGMAR1 (0.48) | SIGMAR1HTR7PPARGPPARAKDM4E | |
| SCHEMBL4588826 | 0.96 | SIGMAR1 (0.47) | SIGMAR1HTR7PPARGPPARAKDM4E | |
| Hydrochloric Acid SCHEMBL4588524 | 0.96 | SIGMAR1 (0.47) | SIGMAR1HTR7PPARGPPARAKDM4E | |
| Hydrochloric Acid SCHEMBL4589225 | 0.95 | SIGMAR1 (0.47) | SIGMAR1HTR7PPARGPPARAKDM4E | |
| SCHEMBL4587598 | 0.94 | SIGMAR1 (0.56) | SIGMAR1HTR7PPARGPPARAKDM4E | |
| Hydrochloric Acid SCHEMBL4589780 | 0.93 | SIGMAR1 (0.55) | SIGMAR1HTR7PPARGPPARAKDM4E | |
| SCHEMBL4587147 | 0.93 | SIGMAR1 (0.55) | SIGMAR1HTR7PPARGPPARAKDM4E | |
| SCHEMBL4589087 | 0.92 | PPARG (0.50) | SIGMAR1HTR7PPARGPPARAKDM4E | |
| Hydrochloric Acid SCHEMBL5354134 | 0.92 | SIGMAR1 (0.54) | SIGMAR1HTR7PPARGPPARAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6936621-B2 | Use of benzoylalkyl-1,2,3,6-tetrahydropyridines | SANOFI-AVENTIS (FR) | 2005-08-30 | — | — | US | claimed |
| US-20040122032-A1 | Use of benzoylalkyl-1,2,3,6-tetrahydropyridines | SANOFI-AVENTIS (FR) | 2004-06-24 | — | — | US | claimed |
| EP-0979079-B1 | USE OF TETRAHYDROPYRIDINE DERIVATIVES TO PREPARE MEDICINES FOR TREATING DISEASES CAUSING DEMYELINATION | SANOFI SYNTHELABO (FR) | 2004-06-16 | — | — | EP | claimed |
| US-20020058672-A1 | Use of benzoylalkyl-1,2,3,6-tetrahydropyridines | BARONI MARCO (IT) | 2002-05-16 | — | — | US | claimed |
| US-6344464-B1 | Use of tetrahydropyridine derivatives to prepare medicines for treating diseases causing demyelination | SANOFI-SYNTHELABO (FR) | 2002-02-05 | — | — | US | claimed |
| EP-0950053-A1 | USE OF BENZOYLALKYL-1,2,3,6-TETRAHYDROPYRIDINS | SANOFI (FR) | 1999-10-20 | — | — | EP | claimed |
| WO-1998028274-A1 | USE OF BENZOYLALKYL-1,2,3,6-TETRAHYDROPYRIDINS | SANOFI (FR) | 1998-07-02 | — | — | WO | claimed |
| US-7320982-B2 | Use of 4-substituted tetrahydropyridines for the manufacture of medicaments acting upon TGF-β 1 | SANOFI-AVENTIS (FR) | 2008-01-22 | — | — | US | disclosed |
| US-7297799-B2 | Preparation of benzoylalkyl-1,2,3,6-tetrahydropyridines and use thereof | SANOFI-AVENTIS (FR) | 2007-11-20 | — | — | US | disclosed |
| US-20070054931-A1 | PREPARATION OF BENZOYLALKYL-1,2,3,6-TETRAHYDROPYRIDINES AND USE THEREOF | SANOFI-AVENTIS (FR) | 2007-03-08 | — | — | US | disclosed |
| US-7151107-B2 | Use of benzoylalkyl-1,2,3,6-tetrahydropyridines | SANOFI-AVENTIS (FR) | 2006-12-19 | — | — | US | disclosed |
| US-20050222187-A1 | Use of benzoylalkyl-1,2,3,6-tetrahydropyridines | SANOFI-AVENTIS (FR) | 2005-10-06 | — | — | US | disclosed |
| US-6936621-B2 | Use of benzoylalkyl-1,2,3,6-tetrahydropyridines | SANOFI-AVENTIS (FR) | 2005-08-30 | — | — | US | disclosed |
| US-20020091143-A1 | Use of 4-substituted tetrahydropyridines for the manufacture of medicament s acting upon TGF-beta 1 | SANOFI-AVENTIS (FR) | 2002-07-11 | — | — | US | disclosed |
| US-20020058672-A1 | Use of benzoylalkyl-1,2,3,6-tetrahydropyridines | BARONI MARCO (IT) | 2002-05-16 | — | — | US | disclosed |
| US-6358965-B1 | THERAPY AND/OR PROPHYLAXIS OF DISEASES WHICH INVOLVE NEURONAL DEGENERATION BY ADMINISTERING BENZOYL-1,2,3,6-TETRAHYDROPYRIDINES COMPOUND | SANOFI-SYNTHELABO (FR) | 2002-03-19 | — | — | US | disclosed |
| US-6344464-B1 | Use of tetrahydropyridine derivatives to prepare medicines for treating diseases causing demyelination | SANOFI-SYNTHELABO (FR) | 2002-02-05 | — | — | US | disclosed |
| US-6342505-B1 | inhibiting apoptosis using xaliproden hydrochloride, or other tetrahydropyridine derivatives | SANOFI-SYNTHELABO (FR) | 2002-01-29 | — | — | US | disclosed |
| EP-0950053-A1 | USE OF BENZOYLALKYL-1,2,3,6-TETRAHYDROPYRIDINS | SANOFI (FR) | 1999-10-20 | — | — | EP | disclosed |
| WO-1998028274-A1 | USE OF BENZOYLALKYL-1,2,3,6-TETRAHYDROPYRIDINS | SANOFI (FR) | 1998-07-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020058672-A1 | Use of benzoylalkyl-1,2,3,6-tetrahydropyridines | KCNH1, KCNJ2, CACNA1B | SIGMAR1 481/4885HTR7 434/4885PPARG 3986/4885 |
| US-20020091143-A1 | Use of 4-substituted tetrahydropyridines for the manufacture of medicament s acting upon TGF-beta 1 | TGFB1, TGFBR1, TGFB2 | SIGMAR1 1163/4885HTR7 2062/4885PPARG 2860/4885 |
| US-20040122032-A1 | Use of benzoylalkyl-1,2,3,6-tetrahydropyridines | KCNH1, KCNJ2, CACNA1B | SIGMAR1 481/4885HTR7 434/4885PPARG 3986/4885 |
| US-20070054931-A1 | PREPARATION OF BENZOYLALKYL-1,2,3,6-TETRAHYDROPYRIDINES AND USE THEREOF | BDNF, KCNH1, GABRA6 | SIGMAR1 695/4885HTR7 328/4885PPARG 3161/4885 |
| US-20050222187-A1 | Use of benzoylalkyl-1,2,3,6-tetrahydropyridines | KCNH1, ATP6V1B2, KCNJ6 | SIGMAR1 491/4885HTR7 282/4885PPARG 3634/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.